OpenAI acquires biotech startup Orchestra Bio

OpenAI has announced the acquisition of Orchestra Bio, a four-year-old software startup specializing in artificial intelligence for biotechnology. While the financial terms of the deal were not disclosed, reports indicate that Orchestra Bio had previously raised approximately $20 million from investors including Andreessen Horowitz, Atria, and 8VC.

The acquisition aims to integrate Orchestra Bio’s team and technology into OpenAI’s life sciences ecosystem, specifically the Rosalind model and the Rosalind Workbench. Orchestra Bio develops AI agents designed to manage the operational complexities of drug discovery, such as tracking finances, monitoring clinical trial schedules, and coordinating workflows between disconnected departmental systems.

By combining these capabilities, OpenAI intends to streamline the transition from scientific discovery to clinical application. This move addresses the significant time lag in drug development, which typically takes 10 to 15 years from target identification to regulatory approval. The integrated tools will assist researchers in planning experiments, analyzing results, and managing the logistical minutiae required to advance potential treatments to patients.